Wake Forest School of Medicine

The Caris Precision Oncology Alliance Welcomes Atrium Health Levine Cancer

Retrieved on: 
Tuesday, October 31, 2023
Intelligence, Wake Forest School of Medicine, MD, MBA, Research, Estate (law), POA, Database, Medicine, Machine learning, Atrium Health Wake Forest Baptist, FACP, Cancer, Patient, Philosophy, Dentistry, Medical imaging

IRVING, Texas, Oct. 31, 2023 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition, announced today that Atrium Health Levine Cancer, an integrated cancer program that unites cancer services at Atrium Health Levine Cancer Institute and Atrium Health Wake Forest Baptist, has joined the Caris Precision Oncology Alliance™ (POA).

Key Points: 
  • Atrium Health Levine Cancer, which includes Atrium Health Levine Cancer Institute and Atrium Health Wake Forest Baptist, joins Caris' extensive network of leading cancer institutions and research consortia committed to improving patient outcomes through innovations in precision medicine
    IRVING, Texas, Oct. 31, 2023 /PRNewswire/ -- Caris Life Sciences ®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition, announced today that Atrium Health Levine Cancer, an integrated cancer program that unites cancer services at Atrium Health Levine Cancer Institute and Atrium Health Wake Forest Baptist, has joined the Caris Precision Oncology Alliance™ (POA).
  • Atrium Health Levine Cancer represents the largest cancer program in the Carolinas and is one of the largest programs in the Southeast.
  • "We are delighted to join the Caris Precision Oncology Alliance and its growing research network," said Ruben A. Mesa, MD, FACP, President of Atrium Health Levine Cancer and Executive Director of Atrium Health Wake Forest Baptist Comprehensive Cancer Center.
  • "We are thrilled to welcome Atrium Health Levine Cancer, which combines Atrium Health Wake Forest Baptist Comprehensive Cancer with legacy POA member Levine Cancer Institute, to the Caris Precision Oncology Alliance," said Chadi Nabhan , MD, MBA, FACP, Chairman of the POA.

Pulmonary Fibrosis Foundation Announces PFF Summit 2023

Retrieved on: 
Wednesday, September 27, 2023
CME, CE, Maintenance, Critical care, Federal, Drug development, Wake Forest School of Medicine, Education, Friends, Cystic Fibrosis Foundation, Convention, COVID-19, ILD, Research, COVID, CMO, Critical Role, Certification, Pulmonary fibrosis, Clinical trial, Boehringer Ingelheim, Hospice, Pharmacist, Patient, Division, Physician, Nursing, Nursing care plan, PFF, MOC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, PF, Lake, Conference, Food, Caregiver, Medical device, Nightclub, Medicine

CHICAGO, Sept. 27, 2023 /PRNewswire/ -- The Pulmonary Fibrosis Foundation (PFF) will present its biennial PFF Summit 2023 from Nov. 9-11 in Orlando, Fla. The three-day international conference, focused on pulmonary fibrosis (PF) and interstitial lung disease (ILD) research and education, will be held at the JW Marriott Orlando Grande Lakes. The PFF Summit welcomes patients, caregivers, healthcare providers and researchers to discuss the latest information on treatment options and how to live well with PF and ILD.

Key Points: 
  • CHICAGO, Sept. 27, 2023 /PRNewswire/ -- The Pulmonary Fibrosis Foundation (PFF) will present its biennial PFF Summit 2023 from Nov. 9-11 in Orlando, Fla.
  • "We are eager to connect patients with one another and with physicians and researchers at the PFF Summit 2023," said Dr. Franck Rahaghi, President, CEO and CMO of the PFF.
  • The PFF Summit 2023 features sessions tailored to each group's experience with PF.
  • The PFF Summit 2023 is made possible by the generous support of Boehringer Ingelheim, the Hales Family Foundation, and other individual and corporate donors.

INTERNATIONALLY RENOWNED DERMATOLOGIST AND PHYSICIAN SCIENTIST SHAWN KWATRA, MD, NAMED NEW CHAIR OF DERMATOLOGY AT THE UM SCHOOL OF MEDICINE AND CHIEF OF SERVICE OF DERMATOLOGY AT UM MEDICAL CENTER

Retrieved on: 
Monday, September 18, 2023
The New England Journal of Medicine, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Medical Affairs Bureau, Society, University of Maryland, College Park, Atopic dermatitis, Skin condition, Science, Maryland School, JAMA Dermatology, Hospital, Journal, Faculty, Prurigo nodularis, University, Physician, Service, Research, Paul Khavari, Johns Hopkins School of Medicine, Human musculoskeletal system, Knowledge, NIH, Skin, Duke University, Arthritis, Immunotherapy, FPI, University of Maryland School of Medicine, Diving Medical Advisory Council, MPH, University of Maryland Medical Center, Vinay Mohan Kwatra, UMMC, Wake Forest School of Medicine, Nature Medicine, UMMS, Joseph, Assistant professor, Pharmaceutical industry, Management, Medical device, Nursing, MD, Dermatology

Dr. Kwatra, who will begin the new role in early 2024, will hold the Joseph W. Burnett Endowed Professor and Chair in Dermatology.

Key Points: 
  • Dr. Kwatra, who will begin the new role in early 2024, will hold the Joseph W. Burnett Endowed Professor and Chair in Dermatology.
  • Dr. Kwatra joins UMSOM from Johns Hopkins University School of Medicine, where he served as the Founding Director of the Johns Hopkins Itch Center.
  • "It is an honor to be the next Chair of Dermatology at such a prestigious medical school," said Kwatra.
  • He earned his undergraduate degree from Duke University and his medical degree from Wake Forest University School of Medicine.

Perfect Corp. to Showcase Game-Changing Generative AI Technologies at the 2023 Global Beauty & Fashion Tech Forum

Retrieved on: 
Wednesday, June 21, 2023
Software, Entertainment, Mobile Entertainment, Social Media, Luxury, Apps, Applications, Technology, Artificial Intelligence, Fashion, Cosmetics, Retail, Communications, Learning, Advertising, PM, Ear, Marketing, Augmented reality, Synthetic media, Skin, Multimedia, Dermatology, Digital technology, Wake Forest School of Medicine, Beauty, Learning Technology Partners, Digital transformation, Physician, Chief digital officer, Generative, Artificial intelligence, Jewellery, AI, MED, Hand, NYSE, AR, PERF, Social media, Clothing, Sales, Powder metallurgy, Medicine

Perfect Corp. (NYSE: PERF), the leading artificial intelligence (AI) and augmented reality (AR) beauty and fashion tech solutions provider, announce the final agenda for the highly-anticipated franchise event, The Global Beauty and Fashion Tech Forum .

Key Points: 
  • Perfect Corp. (NYSE: PERF), the leading artificial intelligence (AI) and augmented reality (AR) beauty and fashion tech solutions provider, announce the final agenda for the highly-anticipated franchise event, The Global Beauty and Fashion Tech Forum .
  • View the full release here: https://www.businesswire.com/news/home/20230621294779/en/
    This year’s forum will showcase the most advanced generative AI technologies that are transforming the beauty and fashion industries today.
  • (Graphic: Business Wire)
    This year’s Global Beauty and Fashion Tech Forum will reveal the next phase of AI innovations with Generative AI technologies.
  • “This year at the Global Beauty and Fashion Tech Forum, we will reveal our most recent breakthroughs on generative AI technologies for fashion and beauty industries,” shares Perfect Corp.

CIRCULOGENE's liquid biopsy for PD-L1 status features in research presented at the recent AACR annual meeting

Retrieved on: 
Friday, May 12, 2023
University of Florida Cancer and Genetics Research Complex, DNA, AACR, Wake Forest School of Medicine, ICI, Hematology, Liquid biopsy, Cancer, Toxicity, Research, Biomarker, RNA, Immunotherapy, Associate, Messenger, Plasma, American Association for Cancer Research, Patient, Immune system, Wake Forest University School of Divinity, CFRNA, Immunohistochemistry, Poster, Neoplasm, Oncology, Liquid, PD-L1, Breast cancer, Pharmaceutical industry, Medical imaging, Medicine

BIRMINGHAM, Ala. and PENSACOLA, Fla., May 12, 2023 /PRNewswire-PRWeb/ -- CIRCULOGENE is an innovative diagnostic company transforming precision medicine through the rapid delivery of actionable results. New research presented by Dr. Lowell Hart at the April 14-19 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida relied upon use of CIRCULOGENE's technology to identify biomarkers which indicate the efficacy of immune checkpoint inhibitors (ICI) therapy.

Key Points: 
  • New research presented by Dr. Lowell Hart at the April 14-19 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida relied upon use of CIRCULOGENE's technology to identify biomarkers which indicate the efficacy of immune checkpoint inhibitors (ICI) therapy.
  • The use of liquid biopsy could improve patient selection for ICI therapy and help clinicians to avoid unnecessary treatment-related toxicity in patients.
  • Liquid biopsies offer a less invasive approach to sampling tumor biology and a more accurate way to assess potential therapeutic response.
  • "And it's exciting to help patients benefit from immune checkpoint inhibitors who previously might not have had the opportunity."

Novan Announces Publication of Psoriasis Patient Data Demonstrating Need for Rapid Symptom Improvement¹

Retrieved on: 
Thursday, April 27, 2023
Cream, National Psoriasis Foundation, Wake Forest School of Medicine, JDD, MC2, Novin, Scalp, Vitamin D, Psoriasis, Journal, Patient, Physician, Calcipotriol, Therapy, Pharmaceutical industry, Dermatology, Medicine

DURHAM, N.C. and COPENHAGEN, Denmark, April 27, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), and MC2 Therapeutics today announced that results of a recently conducted survey to assess psoriasis patients’ topical treatment experience, expectations, and preferences have been published in the Journal of Drugs in Dermatology (JDD). The survey was conducted by the National Psoriasis Foundation and was sponsored by the Company. Most of the participants self-reported having moderate psoriasis (83.9%); most were using systemic therapies (73.5%) and employing topical medications at least once per week (84%).

Key Points: 
  • The survey was conducted by the National Psoriasis Foundation and was sponsored by the Company.
  • Most of the participants self-reported having moderate psoriasis (83.9%); most were using systemic therapies (73.5%) and employing topical medications at least once per week (84%).
  • Understanding what factors impact adherence can help guide physicians in our choice of topical psoriasis treatments.” commented Steven R. Feldman, M.D., Ph.D., Professor of Dermatology, Wake Forest University School of Medicine.
  • “Findings from this survey demonstrated that psoriasis patients expect to see rapid improvement of their symptoms, or they report they will discontinue topical treatment.

Hevolution/AFAR New Investigator Awards in Aging Biology and Geroscience Recipients Announced

Retrieved on: 
Tuesday, April 18, 2023
Research, Philanthropy, Other Health, Biotechnology, Alternative Medicine, General Health, Health, Foundation, Science, Other Science, University of Texas Southwestern Medical Center, Exercise, American Federation for Aging Research, Workforce, Neuron, BAT, Partnership, University of Pittsburgh, University, University of Oklahoma Health Sciences Center, Wake Forest School of Medicine, Therapy, Associate professor, Monash University, Boston University Chobanian & Avedisian School of Medicine, Ageing, University of New South Wales, Brain, Primary ovarian insufficiency, Intravital microscopy, Research fellow, Doctor of Philosophy, American Federation of Aviculture, Assistant, Boston University School of Public Health, EDM, Notifiable disease, AFAR, Assistant professor, National Center for Advancing Translational Sciences, Lipid metabolism, Senescence, Biology, Wound healing, Pharmaceutical industry, Management, Nursing

Hevolution Foundation and the American Federation for Aging Research ( AFAR ) are pleased to announce the inaugural Hevolution/AFAR New Investigator Awards in Aging Biology and Geroscience Research recipients.

Key Points: 
  • Hevolution Foundation and the American Federation for Aging Research ( AFAR ) are pleased to announce the inaugural Hevolution/AFAR New Investigator Awards in Aging Biology and Geroscience Research recipients.
  • Eighteen three-year awards of $375,000 each, for a total of $6.75 Million, have been granted to support research projects in the basic biology of aging or geroscience, a research paradigm based on addressing the biology of aging and age-related disease to promote healthy aging.
  • “Some of the biggest breakthroughs in aging research today were funded first through AFAR’s grants for promising early career researchers.
  • The Hevolution/AFAR New Investigator Awards in Aging Biology and Geroscience Research will significantly boost support for junior faculty worldwide,” noted Stephanie Lederman, EdM, Executive Director, AFAR.

Progress in New Alzheimer's Therapeutics Based on Biology of Aging Highlighted in Symposium Hosted by Alzheimer's Drug Discovery Foundation (ADDF) at AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Dis

Retrieved on: 
Tuesday, March 21, 2023
Fillit, Reverse-path forwarding, Swedish Exhibition & Congress Centre, LSP, Investment, Drug discovery, Disease, Alzheimer's Drug Discovery Foundation, Ageing, Alzheimer's Research UK, Dementia, Cancer, Cognition, MBA, Research, Brain, Doctor of Philosophy, ARUK, Organization, DSM-IV codes, EQT, International Conference on Emerging Infectious Diseases, Homogeneity and heterogeneity, Wake Forest School of Medicine, Drug development, Gates Ventures, Biology, Entrepreneurship, AD, Building a Future, Therapy, Conference, Pharmaceutical industry, Management, Medical imaging, Alzheimer's disease, MD

NEW YORK, March 21, 2023 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation will host a symposium, "Building the Future: Novel Approaches and Innovations in Alzheimer's Research" at the AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders, March 28th through April 1st at the Swedish Exhibition & Congress Centre in Gothenburg, Sweden.

Key Points: 
  • This symposium encompasses two sessions.
  • The second session, "Emerging Solutions: Novel Approaches to Treating Alzheimer's Disease," focuses on the biology of aging and promising drugs in the pipeline that target a host of underlying pathologies that contribute to Alzheimer's disease.
  • It features presentations on research, including novel senolytics and repurposing programs, as well as prevention approaches for Alzheimer's and related dementias.
  • These diverse approaches reflect the current Alzheimer's pipeline, where 75% of drugs in clinical trials focus on non-amyloid and tau targets according to a recent report.

Dr. B. Hadley Wilson is New American College of Cardiology President

Retrieved on: 
Monday, March 6, 2023
Wake Forest School of Medicine, Registry, Science, Health, College, Davidson College, American College of Cardiology, FACC, Cardiovascular disease, Education, RN, Duke University School of Medicine, Florida Board of Governors, Cardiology, Catheter, Patient, Multimedia, Wilson, MSN, Medical missions, Knowledge, Health policy, Vanderbilt University, Doctor of Philosophy, NCDR, American College, Internal medicine, ACC, Nursing, Dentistry, MD, Trustee

NEW ORLEANS, March 6, 2023 /PRNewswire/ -- B. Hadley Wilson, MD, FACC, is the new president of the American College of Cardiology.

Key Points: 
  • NEW ORLEANS, March 6, 2023 /PRNewswire/ -- B. Hadley Wilson, MD, FACC, is the new president of the American College of Cardiology.
  • B. Hadley Wilson, MD, FACC, is the new president of the American College of Cardiology.
  • After completing his cardiology fellowship, Wilson joined Sanger Heart and Vascular Institute as an interventional cardiologist and served as director of the catheterization laboratory and chief of cardiology for 15 years.
  • The American College of Cardiology (ACC) is the global leader in transforming cardiovascular care and improving heart health for all.

Cetaphil® unveils digital AI skin analysis tool to empower and educate users with sensitive skin

Retrieved on: 
Thursday, March 2, 2023
Acne, AI, Wake Forest School of Medicine, Patient, Deep learning, Database, Skin, Cetaphil, QR, Red, Cosmetics, Medical device, Dermatology

The AI skin analysis tool is powered by Perfect Corp's AI Skin Analysis technology and provides a clear, easy-to-follow user experience on the Cetaphil U.S. website.

Key Points: 
  • The AI skin analysis tool is powered by Perfect Corp's AI Skin Analysis technology and provides a clear, easy-to-follow user experience on the Cetaphil U.S. website.
  • The innovative skin scanning technology features cutting-edge AI deep learning technology to deliver precise, personalized skin assessments in seconds.
  • 's AI Skin Analysis Technology recently underwent validation testing with Dr. Steven R. Feldman, Professor of Dermatology at the Wake Forest School of Medicine.
  • "AI skin tech can be a fantastic tool and useful first step in gaining an understanding of one's personal skincare needs.